Fish oil supplement tested for muscle loss in liver cancer patients

NCT ID NCT07664007

Completed Disease control Sponsor: Instituto de Investigación Sanitaria Aragón Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12 weeks alongside their standard chemotherapy. The study measured changes in muscle mass using CT scans and assessed nutritional status.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eicosapentaenoic acid (EPA) supplement
What this could lead to: If it works, this could point toward a simple nutritional supplement to help maintain muscle mass and reduce inflammation in people with advanced liver cancer.
What could go wrong: This was a very small, early-stage trial with only 18 participants, so results may not apply widely. The supplement may not provide meaningful benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia hepatocellular carcinoma Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Hospital Clínico Universitario Lozano Blesa. IIS Aragón

Zaragoza, Zaragoza, 50009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.